{"organizations": [], "uuid": "7d88fe9d1bc03fc4b3a510b6b52c990abdb8dbbd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180523.html", "section_title": "Archive News &amp; Video for Wednesday, 23 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-immune-pharmaceuticals-provides-pi/brief-immune-pharmaceuticals-provides-pipeline-update-idUSASC0A3DF", "country": "US", "domain_rank": 408, "title": "BRIEF-Immune Pharmaceuticals Provides Pipeline Update", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-23T21:27:00.000+03:00", "replies_count": 0, "uuid": "7d88fe9d1bc03fc4b3a510b6b52c990abdb8dbbd"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-immune-pharmaceuticals-provides-pi/brief-immune-pharmaceuticals-provides-pipeline-update-idUSASC0A3DF", "ord_in_thread": 0, "title": "BRIEF-Immune Pharmaceuticals Provides Pipeline Update", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "immune pharmaceuticals inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "nanocyclo", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 23 (Reuters) - Immune Pharmaceuticals Inc:\n* IMMUNE PHARMACEUTICALS PROVIDES A PIPELINE UPDATE * IMMUNE PHARMACEUTICALS INC - CONTINUE DISCUSSIONS WITH PARTIES POTENTIALLY INTERESTED IN ACQUIRING CERTAIN OF CYTOVIAâ€™S ASSETS\n* IMMUNE PHARMACEUTICALS INC - HAS BEGUN PLANNING FOR A RANDOMIZED, CONTROLLED PHASE 2/3 TRIAL TO LAUNCH IN 2019 FOR BERTILIMUMAB\n* IMMUNE PHARMACEUTICALS - PREPARING FOR MEETINGS WITH FDA, EMA LATER IN YEAR TO DISCUSS PLANNED PHASE 2/3 STUDY, MANUFACTURING PLANS FOR BERTILIMUMAB\n* IMMUNE PHARMACEUTICALS INC - CURRENTLY PLANNING A TOXICITY STUDY TO BEGIN IN Q3 FOR NANOCYCLO\n* IMMUNE PHARMACEUTICALS INC - EXPECTS TO COMMENCE PLANNED PROOF-OF-CONCEPT CLINICAL TRIAL LATE IN Q4 2018 OR EARLY Q1 2019 FOR NANOCYCLO Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-23T21:27:00.000+03:00", "crawled": "2018-05-24T20:35:53.017+03:00", "highlightTitle": ""}